- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02970422
Chronic Obstructive Pulmonary Disease Patient Preferences Survey
COPD Patient Preferences, Activities, and Participation Survey
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, H4A 3J1
- Montreal Chest Institute of the McGill University Health Center (MUHC)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Clinical diagnosis of COPD
- English or French speaking
- Patient at one of the three participating sites with medical chart
Exclusion Criteria:
- No diagnosis of COPD by a healthcare professional
- Unable to communicate in English or French
- Unable to provide informed consent
- No medical chart information at one of the three participating sites
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Quartile 1 [Mild]
|
Participants will answer an online survey and their medical chart information will be gathered to compare responses across disease severity.
|
|
Quartile 2 [Moderate]
|
Participants will answer an online survey and their medical chart information will be gathered to compare responses across disease severity.
|
|
Quartile 3 [Severe]
|
Participants will answer an online survey and their medical chart information will be gathered to compare responses across disease severity.
|
|
Quartile 4 [Very Severe]
|
Participants will answer an online survey and their medical chart information will be gathered to compare responses across disease severity.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants Who Prioritized Healthcare Topics
Time Frame: Baseline
|
Twenty-four healthcare topics were selected once again from a literature and expert panel review, as well as corroborated by individuals living with COPD in five focus groups.
Example healthcare topics include: relief of breathlessness; increase maximal amount of exercise individuals living with COPD can do inside and outside their homes; and prevent-lung flare-ups.
Participants were asked to indicate their preference of the topics by assigning a percentage of their time, in increments of 10%, to the various healthcare topics, for a total of 100% of their time.
For the 24 healthcare topics, individuals could select up to 10 topics (10% times 10 topics, for 100% of their time).
The top five topics are presented as the most important topics for the participants and are indicative of areas of focus for future healthcare and research.
The top five were presented in accordance to the request from the working group who developed the survey and reviewed the results.
|
Baseline
|
|
Number of Participants Who Prioritized Research Topics
Time Frame: Baseline
|
Individuals were asked to indicate their research priorities from a list of research topics using a modified willingness-to-pay method (Kawata et al., 2014).
The willingness-to-pay method allows individuals to assign preference to various topics by assigning a percentage of funds to the topic.
A list of 22 research topics (e.g., to relieve breathlessness in individuals living with COPD, to increase access to lung transplantations) was created for this study through a literature review, expert consultation, and five focus groups with individuals living with COPD (n=23, 27% women).
Individuals were asked to assign a percentage of funds, in increments of 10% of funding, to the 22 COPD research topics.
Participants could assign anywhere between 10% of funding to 100% of funding to the topics.
The top five were presented in accordance to the request from the working group who developed the survey and reviewed the results.
|
Baseline
|
|
Number of Participants Who Were Not Satisfied With Their Participation in Daily and Social Activities
Time Frame: Baseline
|
Participants will answer questions about their participation in 26 daily activities, as well as their desire to participate in each of the 26 daily activities. This is a measure of those who indicated they wanted to increase their participation. 10 of the 26 activities and their outcome measures are listed below. Activity 1: Walking from one place to another outside of your home on a flat surface. Activity 2: Moving from one place to another using motorized transportation. Activity 3: Climbing two or more flights of stairs. Activity 4: Walking up a hill. Activity 5: Participating in regular exercise. Activity 6: Walking from one place to another in your home. Activity 7: Carrying light objects on a flat surface. Activity 8: Carrying heavy objects on a flat surface. Activity 9: Carrying-out low intensity physical activities |
Baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Forced Expiratory Volume in 1-sec (FEV1)
Time Frame: Baseline
|
Individuals forced expiratory volume in 1-sec (FEV1) as assessed by spirometry
|
Baseline
|
|
FEV1/FVC
Time Frame: Baseline
|
Individuals FEV1-to-forced vital capacity (FVC) ratio
|
Baseline
|
|
Modified Medical Research Council Questionnaire on Breathlessness
Time Frame: Baseline
|
Self-reported intensity of activity related breathlessness as assessed by the modified Medical Research Council (mMRC) dyspnea scale (0-4).
This questionnaire was used to measure participants' breathlessness burden using a single item scale from 0 to 4, where a score of 0-1 indicated mild breathlessness and 2-4 indicated increased breathlessness.
|
Baseline
|
|
COPD Assessment Test
Time Frame: Baseline
|
This questionnaire measure the impact COPD is having on well being and daily life.
The CAT is an eight-item semantic differential scale from 0 to 5, where 0 is no impact and 5 is extremely impactful.
Items include: I never cough| I cough all the time, I have no phlegm (mucus) in my chest at all | My chest is completely full of phlegm (mucus), My chest does not feel tight at all | My chest feels very tight, When I walk up a hill or one flight of stairs, I am not breathless | When I walk up a hill or one flight of stairs, I am very breathless, I am not limited doing any activities at home| I am very limited doing activities at home, I am confident leaving my home despite my lung condition| I am not at all confident leaving my home because of my lung condition, I sleep soundly | I don't sleep soundly because of my lung condition, I have lots of energy I have no energy at all.
Participants' scores were totaled and a score of ≥ 10 indicated higher than normal burden of disease.
|
Baseline
|
|
Godin Leisure Time Physical Activity Questionnaire
Time Frame: Baseline
|
Self-reported physical activity levels measured in length of bouts over the previous 7 days to determine physical activity frequency.
|
Baseline
|
|
Satisfaction of Life Questionnaire
Time Frame: Baseline
|
This 5 item questionnaire was used to measure participants' level of life satisfaction.
The higher the score, the higher the sense of life satisfaction.
A score from 5-9 indicated extremely dissatisfied, 10-14 is dissatisfied, 15-19 indicated slightly below average life satisfaction.
20-24 is the average score, 25-29 is a high score indicative of higher life satisfaction and a score between 30-35 is a very high score and represent very high life satisfaction.
|
Baseline
|
|
Number of Participants With Exacerbations Due to COPD in the Preceding 12 Months
Time Frame: baseline
|
An exacerbation was defined as a change in medication due to a COPD exacerbation (i.e., the prescription of prednisone or a medical action plan) as indicated in the medical chart or hospital admission due to a COPD exacerbation.
|
baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Shane N Sweet, Ph.D., McGill University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 15-203-MUHC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Disease, Chronic Obstructive
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
University of LeicesterUniversity Hospitals, Leicester; University of StrathclydeRecruitingChronic Obstructive Pulmonary Disease (COPD) | Chronic Obstructive Lung Disease | Chronic Obstructive Airway DiseaseUnited Kingdom
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
Mylan Inc.Theravance BiopharmaCompletedChronic Obstructive Pulmonary Disease (COPD)United States
-
University Hospital, GhentGlaxoSmithKline; University GhentCompletedChronic Obstructive Pulmonary Disease (COPD)Belgium
-
Optimum Patient CareRespiratory Effectiveness Group; Boehringer Ingelheim Pharmaceutical Company... and other collaboratorsUnknownChronic Obstructive Pulmonary Disease (13645005)United States
-
Poitiers University HospitalCompletedBroncho Chronic Obstructive Pulmonary DiseaseFrance
Clinical Trials on Patient Survey
-
Sarasota Memorial Health Care SystemEnrolling by invitation
-
Ohio State UniversityWithdrawnMedicare Part DUnited States
-
Memorial Sloan Kettering Cancer CenterCompletedInpatients With Limited English ProficiencyUnited States
-
University of AarhusUniversity of Rwanda; Mental Health Centre CopenhagenUnknownBipolar Disorder | Mental Disorder
-
University of Colorado, DenverUniversity of California, Los Angeles; University of Michigan; University of... and other collaboratorsRecruitingBarrett Esophagus | Gastro Esophageal Reflux DiseaseUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteCompleted
-
Stanford UniversityCompletedAdenocarcinoma | Squamous Cell Carcinoma | CarcinomasUnited States
-
University Hospital, Basel, SwitzerlandCompleted
-
Abbott Medical DevicesCompletedBradycardia | Cardiac Rhythm Disorder | Cardiac Pacemaker ArtificialUnited States
-
Seoul National University HospitalSamsung Medical Center; Korea University Anam Hospital; Catholic Medical Center...Enrolling by invitationLymphoplasmacytic Lymphoma | Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) | Follicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Marginal Zone Lymphoma(MZL) | Waldenström Macroglobulinemia (WM)South Korea